Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with ...

The majority of working-age patients with postacute sequelae of COVID-19/PCS do not recover in the second year of their illness.

Dexamethasone reduced mortality among patients hospitalized with COVID-19, especially those who were also receiving respiratory support.

Opioid-related neurocognitive symptoms among patients on long-term opioid therapy were most prevalent during the course of therapy.

The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.

On a global scale, childhood maltreatment is associated with a higher risk for developing some immune-mediated inflammatory disorders.

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

President Trump has ended a Biden administration effort to lower the cost of prescription drugs for people on Medicare and Medicaid.